Rentschler Biopharma provides update on personnel change in company’s extended executive team

Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), announced today that Federico Pollano, Senior Vice President Business Development & Client Program Management and member of the Executive Committee, will pursue new career opportunities and leave the company on February 28, 2025. Benedikt von Braunmühl, CEO of Rentschler Biopharma, and Dr. Patrick Meyer, Global Head BD Sales and Alliance Management, will take over the pertinent responsibilities until the new appointment is made.

Benedikt von Braunmühl said: “I would like to express my sincere thanks to Federico for his successful work in business development and client management. Through his outstanding commitment, he has helped to position Rentschler Biopharma as a partner of choice for the development and production of biopharmaceuticals with tailor-made first-in-class solutions. Federico played a key role in integrating business development, and client and project management in the interest of providing seamless client-centric services. During his seven years at Rentschler Biopharma, and under Federico's leadership, the BD team has grown considerably to respond to the global expansion of our company and the broadening of our service offering to encompass new modalities. Together with the Executive Committee and the entire Rentschler Biopharma team, we wish Federico Pollano all the best for his professional and personal future.”

“Dr. Patrick Meyer and I will continue to lead and support our well-trained teams in business development and client program management, ensuring that our client-focused partnerships maintain their high level of reliability,” added von Braunmühl. 

Previously, Dr. Patrick Meyer had been promoted to Global Head BD Sales and Alliance Management in Rentschler Biopharma's within the Business Development team on June 1, 2024. In this newly created position, he has since overseen the company's global business development processes and handled key account management with great success.